China’s First Innovative Drug for Alzheimer’s Disease: GV-971 Marketed at RMB895
By Dishui Sinan
It is learned from the GV-971 Global Strategic Launch and the First Gut-Brain Axis Forum hosted by Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM) on Dec. 29, 2019 that the innovative drug for Alzheimer’s disease (AD)-GV-971 (sodium oligomannurarate) has been officially marketed in China, which is priced at RMB895/box and has attracted much attention of the pharmaceutical practitioners.
Visit En-CPhI.CN to find answers to the 10 questions for the innovative drug for Alzheimer’s disease (AD)-GV-971 (sodium oligomannurarate) to be marketed in China:
https://www.en-cphi.cn/news/show-58700.html
Register as Visitor to CPhI China 2020!
-----------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: [email protected].
If it is proven that this drugs works by even partially improving the Alzheimer's patients disease by modification of Gut Microbiome, it will be real a breakthrough. It will be multi billion USD drug within no time and a feather in the cap of Chinese Pharma industry.